Bloomberg Intelligence: CVS Plans to Spin Off (Podcast)

CVS Health plans to spin off its retail pharmacy business as CVS Pharmacy in the first half of 2028, separating it from Aetna and Caremark; both companies would be publicly traded. CVS shares fell as much as 14% after the announcement. Separately, Uber reported Q3 gross bookings of $59.8 billion and adjusted EPS of $0.88, both around expectations, while AMD forecast Q4 revenue of $17 billion, plus or minus 3%, above the $16.3 billion analyst estimate.

Analysis

CVS: The separation may reduce the conglomerate discount, but it also makes the value of each business—and the costs of disentangling them—more visible. The key risk is that investors capitalize the retail pharmacy separately without giving the remaining insurance/PBM businesses credit for lost purchasing leverage, shared services, or cross-business economics. A 2028 target leaves ample time for execution slippage, debt-allocation disputes, and stranded costs; the announcement alone does not establish that either standalone company will earn better returns. Near term, the sharp selloff raises the bar for fresh shorts: the more useful signal is whether management supplies credible segment economics and a detailed separation plan over the next 1–3 months.

AMD: Stronger near-term data-center demand supports the earnings path, but the second-order test is whether supply and product mix let revenue convert into durable margins—not simply whether demand is present. NVIDIA and custom silicon are competing for the same spending pool, while any customer capex pause could quickly reverse the setup. Over 6–18 months, monitor data-center growth, gross-margin trajectory, and evidence of repeatable orders; one upbeat forecast is not proof of sustained share gains.

UBER: Results merely meeting expectations while the shares rise suggests a favorable reaction, not a new fundamental inflection. The next rerating needs evidence that bookings translate into durable earnings and cash generation after insurance, incentives, and regulatory costs. No compelling directional signal from this update alone.

Key Decisions for Investors

• CVS — Avoid an automatic dip-buy. Keep an underweight versus a broad healthcare benchmark, or add only if the stock fails to recover and subsequent disclosures reveal material stranded costs, unfavorable debt allocation, or weaker standalone economics. Reassess on a detailed separation plan; a credible cost allocation and improving segment outlook would falsify the bearish case.
• AMD — Prefer staged exposure on pullbacks rather than chasing the forecast reaction; a relative long versus a semiconductor-sector basket is reasonable only while data-center demand converts into revenue without margin deterioration. Cut the thesis if guidance is reduced, data-center growth weakens, or gross margins materially disappoint.
• UBER — No incremental trade on an in-line report. Revisit a long only with evidence of improving earnings/cash conversion alongside bookings; deterioration in insurance costs, incentives, or regulatory conditions would argue against it.